Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings
Abbott’s Portico with Flexnav Tavr System Receives the US FDA’s Approval for the Treatment of Aortic Valve Disease
Shots:
- The acquisition will accelerate Abbott’s vascular portfolio with the addition of Walk Vascular’s peripheral thrombectomy systems to treat patients with peripheral blood clots
- Walk Vascular’s JETi & JETi AIO peripheral thrombectomy systems are aspiration systems for the removal of intravascular clots. The systems are supported by RWE, and Walk is currently enrolling ~250 patients in the US and EU in the JETi Registry
- Additionally, both systems have received 510(k) clearance from the FDA for breaking soft emboli and thrombus from the peripheral vasculature to reduce the risk of dislodged clots. The systems also received a CE Mark in the EU and approvals in other countries
Click here to read full press release/ article | Ref: Abbott | Image: Media Post